Compass Group (CMPGY) remains a high-quality compounder, but current valuation leaves limited upside, justifying a 'Hold' rating. CMPGY delivered 9% H1 FY 2026 revenue growth and 12% EBIT growth, outpacing historical rates as international and M&A strategies drive expansion. Organic revenue is guided to ~7% for FY 2026, with EBIT expected to grow 11% and margins benefiting from scale and bolt-on acquisitions.
Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody, after a randomized study in advanced biliary tract cancer met its primary endpoint and a key secondary endpoint.
Compass' stock price plummeted Wednesday after news broke that the New York Attorney General's office was investigating the brokerage over antitrust concerns.
| Hotels, Restaurants & Leisure Industry | Consumer Discretionary Sector | Dominic William Blakemore CEO | XDUS Exchange | US20449X4016 ISIN |
| GB Country | 580,000 Employees | 18 Jun 2026 Last Dividend | 8 Jul 2014 Last Split | - IPO Date |
Compass Group PLC is a leading global food and support services company with operations spanning North America, Europe, and various international markets. Founded in 1941 and headquartered in Chertsey, the United Kingdom, the company has grown to serve a wide range of sectors. These include business and industry, healthcare and senior living, education, sports and leisure, and the defense, offshore, and remote sectors. Compass Group is dedicated to providing high-quality services tailored to the unique needs of its clients, ensuring an optimal balance between efficiency and customer satisfaction.
Compass Group offers a comprehensive range of support services, designed to meet the operational needs of facilities across various sectors. These services include:
Understanding the diverse needs across different markets, Compass Group tailors its offerings to several key sectors: